Report cover image

Rotavirus Vaccines

Published Jun 01, 2025
Length 277 Pages
SKU # GJOB20089234

Description

Global Rotavirus Vaccines Market to Reach US$15.9 Billion by 2030

The global market for Rotavirus Vaccines estimated at US$9.7 Billion in the year 2024, is expected to reach US$15.9 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Rotarix, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Rotateq segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.2% CAGR

The Rotavirus Vaccines market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global "Rotavirus Vaccines" Market – Key Trends & Drivers Summarized

Why Is Rotavirus Vaccination So Vital in Pediatric Healthcare?
Rotavirus remains one of the leading causes of severe diarrheal disease in infants and young children worldwide, despite major advances in sanitation and nutrition. The virus is highly contagious, and once symptomatic, often requires hospitalization due to dehydration. Rotavirus vaccines offer the most effective preventive strategy, dramatically reducing mortality rates, hospital admissions, and treatment costs in both developed and developing countries. The WHO recommends routine rotavirus immunization in national immunization programs, and the results have been compelling: countries that introduced the vaccine saw hospitalizations due to rotavirus decrease by over 80%. Current vaccines—such as Rotarix, RotaTeq, and newer heat-stable versions—are primarily oral and well-tolerated in infants. Furthermore, new entrants are aiming to improve coverage in rural and remote areas with drop-in cold chain alternatives. The critical importance of rotavirus vaccination lies not just in prevention, but in averting strain on pediatric healthcare infrastructure globally.

Are Next-Gen Formulations and Broader Access Models Driving Global Immunization?
New vaccine technologies and expanded manufacturing capabilities are reshaping the rotavirus immunization landscape. Heat-stable formulations that require minimal cold chain storage are being piloted for deployment in remote regions across Africa and Southeast Asia. Additionally, single-dose and neonatal formulations are under development to streamline scheduling and boost compliance. The rise of public-private partnerships, such as those fostered by Gavi, the Vaccine Alliance, is facilitating widespread, subsidized distribution in low-income nations. Equally important is the emergence of local manufacturers in India, China, and Brazil who are producing cost-effective generics and biosimilars, reducing dependency on Western pharma giants. Vaccine coverage is now increasing not only due to logistics but also due to targeted education campaigns aimed at caregivers and community health workers. The combination of scientific advancement and equitable access strategies is setting the stage for a broader and more sustained decline in rotavirus-related morbidity.

Can Surveillance Data and Real-World Outcomes Influence Vaccine Evolution?
Real-world efficacy studies and ongoing epidemiological surveillance are proving essential in refining vaccine strategies for rotavirus. Strain diversity is a known challenge—especially in regions where multiple serotypes co-circulate—and studies have revealed varying degrees of protection across different geographies. This has prompted development of region-specific vaccine blends and enhanced bivalent formulations. Moreover, integration of rotavirus vaccines into digital health registries has allowed for better outcome tracking, adverse event monitoring, and adherence analysis. Longitudinal data shows herd immunity benefits, with even unvaccinated populations experiencing reduced infection rates in high-coverage areas. These insights are helping vaccine makers improve targeting, while allowing governments to reallocate health budgets based on demonstrated impact. Combined with advances in genomic sequencing of rotavirus strains, real-world data is becoming a cornerstone of next-gen vaccine innovation.

What’s Driving Global Expansion of Rotavirus Vaccines Across Health Systems?
The growth in the global rotavirus vaccines market is driven by several factors, notably expanded immunization funding, regional manufacturing capabilities, and vaccine technology innovation. Government mandates for pediatric immunization and WHO prequalification of new vaccine variants are accelerating market access globally. Rising birth rates in Africa and South Asia, coupled with increased awareness among parents and healthcare workers, are strengthening demand. Technological improvements—like thermostable and single-dose oral formulations—are improving logistical feasibility and reducing costs. Subsidized pricing and multilateral procurement frameworks through UNICEF and Gavi have significantly increased vaccine availability in resource-poor settings. Additionally, local clinical trials and approvals in high-burden countries are making rollouts faster and more culturally acceptable. With public health systems focusing on early-life disease prevention, rotavirus vaccines are becoming a staple in routine immunization schedules worldwide.

SCOPE OF STUDY:

The report analyzes the Rotavirus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb, Other Types); End-Use (Hospitals & Clinics, Academic & Research, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -
  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare (Zydus Cadila)
  • Center for Research and Production of Vaccines and Biologicals (POLYVAC)
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

277 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Rotavirus Vaccines – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
High Burden of Pediatric Diarrheal Diseases Drives Demand for Rotavirus Vaccination
Expanded Immunization Programs in Emerging Economies Propel Market Growth
World Health Organization Recommendations Strengthen the Business Case for Global Rollouts
Inclusion of Rotavirus Vaccines in National Immunization Schedules Expands Addressable Market
GAVI and UNICEF Funding Initiatives Generate Access Opportunities in Low-Income Regions
Advancements in Cold Chain Logistics Sustain Growth in Global Distribution
Rising Awareness Campaigns Around Infant Health Spur Vaccine Adoption
Improved Efficacy and Longer Duration of Protection Drive Preference for New Formulations
Ongoing Research on Combination Vaccines Throws the Spotlight on Product Innovation
Efforts to Reduce Child Mortality Rates Reinforce Market Demand
Entry of Low-Cost Manufacturers Boosts Supply in Price-Sensitive Markets
Regulatory Approvals of New Vaccine Variants Accelerate Market Penetration
Public-Private Partnerships Enhance Vaccine Delivery Infrastructure
Surveillance Data and Disease Burden Analytics Drive Policy and Procurement Decisions
Pandemic-Driven Focus on Immunization Resilience Creates Opportunities for Vaccine Market Expansion
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Rotavirus Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Rotarix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Rotateq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Rotavin-M1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Lanzhou Lamb by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Academic & Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Japan 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: China 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: France 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Germany 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Italy 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: UK 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Spain 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Russia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Australia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Australia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
INDIA
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: India 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: India Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: India 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: South Korea 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: South Korea 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
LATIN AMERICA
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Latin America 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Argentina 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Argentina 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Brazil 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Brazil 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Mexico 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Mexico 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
MIDDLE EAST
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Middle East 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Iran 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Iran 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Israel 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Israel 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: UAE 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: UAE 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
AFRICA
Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Africa 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Africa 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
IV. COMPETITION
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.